Should I order genetic testing for a 51-year-old woman whose mother died at age 52 from inflammatory breast cancer?

Yes, you should refer this patient for genetic counseling and testing.

This 51-year-old woman meets clear criteria for genetic counseling and BRCA testing based on her mother's early-onset breast cancer diagnosis (age 52), regardless of the inflammatory subtype. Her family history represents a significant red flag that warrants evaluation for hereditary cancer susceptibility.

Why This Patient Qualifies for Testing

The USPSTF guidelines explicitly recommend genetic counseling and testing for women whose family history suggests increased risk for potentially harmful BRCA mutations 1. Key qualifying factors include:

• Early-age onset in a first-degree relative: Breast cancer diagnosed at age ≤50 years in a close family member is a primary criterion 2, 1
• Mother diagnosed at 52: While just above the typical 50-year threshold, this still represents relatively early onset, particularly for inflammatory breast cancer
• Patient's current age of 51: She is approaching the age at which her mother was diagnosed, making risk assessment and potential interventions particularly time-sensitive

The NCCN guidelines specifically state that women should be referred for genetic evaluation when there is "early-age onset of breast cancer (i.e., ≤ 50 years)" in the family 2. Your patient's mother at age 52 falls into this high-suspicion category, especially given the aggressive inflammatory subtype.

The Inflammatory Breast Cancer Factor

While research shows that inflammatory breast cancer (IBC) itself does not have a significantly higher rate of BRCA mutations compared to non-IBC breast cancers (18.1% vs 27.3% in unmatched cohorts) 3, this should not dissuade you from testing. Among BRCA-positive patients, those with IBC were diagnosed at significantly younger ages 3, suggesting that when hereditary factors are present in IBC families, they may manifest earlier and more aggressively.

Practical Testing Approach

Use a brief risk stratification tool first, then refer for formal genetic counseling:

• The Referral Screening Tool (B-RST) or Family History Screen-7 (FHS-7) are the simplest and quickest to administer 1
• These tools have >85% sensitivity for identifying women who should undergo genetic counseling 1
• Do not use general breast cancer risk tools like the Gail model—they are not designed for determining genetic testing eligibility 1

What Testing Should Include

If proceeding with genetic testing after counseling 4:

• Minimum: BRCA1 and BRCA2 testing
• Preferred: Multi-gene panel including BRCA1, BRCA2, PALB2, TP53, PTEN, STK11, CDH1, ATM, CHEK2, BARD1, NBN, RAD51C, and RAD51D 5, 4
• Recent guidelines emphasize that high-penetrance genes beyond BRCA1/2 (particularly PALB2, TP53, PTEN, STK11, CDH1) can inform surgical decision-making and risk management 4, 6

Critical Timing Considerations

This patient needs testing now, not later, for several reasons:

1. She is at the age when her mother developed cancer—the window for preventive interventions is closing
2. If a pathogenic variant is found, she can pursue enhanced surveillance (annual mammography + MRI starting immediately) 2, 7
3. Risk-reducing strategies (including consideration of prophylactic mastectomy or oophorectomy) are most beneficial when implemented before cancer develops 1, 7
4. Recent data shows that 20-24% of women diagnosed with breast cancer under age 60 carry pathogenic variants 8, 9, and your patient hasn't even been diagnosed yet—she has the opportunity for true prevention

Common Pitfalls to Avoid

• Don't wait for more family history: One first-degree relative with early-onset breast cancer is sufficient 2, 1
• Don't dismiss the case because the mother had IBC: The aggressive subtype doesn't reduce hereditary risk and may actually signal earlier manifestation in mutation carriers 3
• Don't order testing without counseling: Pre-test genetic counseling is essential for informed consent and proper interpretation 2, 1
• Don't assume negative results are reassuring without context: Uninformative-negative results (when no affected relative has been tested) still carry increased breast cancer risk 1

If Testing Reveals a Pathogenic Variant

Management would include 7:

• Clinical breast exams every 6-12 months starting immediately
• Annual mammography + breast MRI
• Discussion of risk-reducing bilateral mastectomy (timing based on patient preference and specific gene)
• Risk-reducing salpingo-oophorectomy (typically age 35-40 for BRCA1/2, after childbearing complete)
• Cascade testing for other at-risk family members

The bottom line: Refer this patient to genetic counseling now. The combination of a first-degree relative with breast cancer at age 52 and the patient's current age of 51 creates a compelling case for immediate evaluation. Early identification of a hereditary predisposition could be life-saving through enhanced surveillance and risk-reduction strategies 1.